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Abstract
Background: Chronic Renal Allograft Dysfunction (CRAD) is responsible for a large number of
graft failures. We have abrogated acute T-cell rejections using Ahmedabad Tolerance Induction
Protocol (ATIP) with hematopoietic stem cell transplantation (HSCT) under non-myeloablative
conditioning pre-transplant. However B-cell mediated rejections and CRAD continue to haunt us.
We carried out retrospective analysis of renal allograft biopsies performed in the last 4 years to
evaluate the effect of ATIP on CRAD.
Materials and methods: Biopsies diagnosed as per modified Banff criteria belonged to 2 groups:
ATIP under low dose immunosuppression of cyclosporine/Azathioprine/Mycofenolate mofetil+
Prednisolone, subjected to donor leucocyte transfusion, anti-T/B cell antibodies, low dose target
specific irradiation, cyclophosphamide, cyclosporin followed by HSCT pre-transplant; controls who
opted out of ATIP were transplanted under standard triple drug immunosuppression.
Demographics of both groups were comparable.
Results: Incidence of chronic changes was higher in controls (17.5%) vs. 10.98% in ATIP over a
mean follow up of 151.9 months in the former and 130.9 months in the latter. Proteinuria and
hypertension were higher in controls (48.4%) vs. ATIP (32.7%) with chronic transplant
glomerulopathy, focal global sclerosis in 67.7% in controls vs. 46.7% in ATIP, acute on chronic T/B
cell rejection in 51.6% controls vs. 28.1% ATIP, with peritubular capillary C4d deposits in 19.4%
controls vs. 1.9% ATIP biopsies. Acute on chronic calcineurin inhibitor toxicity was higher in ATIP
(71.9%) vs. 48.4% in controls.
Conclusion: Chronic immune injury was less with ATIP vs controls as compared to a higher
incidence of chronic calcineurin inhibitor toxicity in the former.
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Background
Significant improvement in 1 year renal allograft and
patient survival rates have been achieved over the last 10
years as a result of newer immunosuppressive regimes and
the increasing use of living donors for transplantation.
However long term graft function and survival rates
remain less than optimal. Up to 50% grafts are lost to
chronic renal allograft dysfunction (CRAD). [1] We have
been modifying Ahmedabad Tolerance Induction Proto-
col (ATIP) to achieve transplantation tolerance in our
renal allograft recipients since 1998. [2] We have effec-
tively abrogated acute T-cell mediated rejections however
we have not been able to address B-cell mediated rejec-
tions and CRAD. The present study aims to evaluate the
effect of ATIP on CRAD in our living-related renal allograft
recipients.
Materials and methods
This was a retrospective study of renal allograft biopsies
performed at our center from January 2004 to December
2007. Out of 1699 patients transplanted from January
1998 to October 2007, 727/1171 (62.1%) ATIP and 312/
528 (59.1%) controls with functioning grafts are on fol-
low-up.
ATIP comprised of administration of donor leucocyte
transfusions, target specific irradiation to sub-diaphrag-
matic lymph nodes, spleen, part of pelvic bones and lum-
bar vertebrae (200 CgY × 5 days), anti-T cell antibody, 1.5
mg/kg BW and anti-B cell antibody, 6 mg/kg BW intrave-
nously respectively followed by unmodified cytokine
stimulated donor derived bone marrow (BM) administra-
tion intraportally fortified with cultured BM derived
hematopoietic stem cells, human adipose tissue derived
mesenchymal stem cells and peripheral blood stem cells
to recipients. Renal transplantation was performed fol-
lowing negative lymphocytotoxicity cross-matching
(LCM) (serology).
Patients belonging to the control group were transplanted
following negative LCM reports. Recipient maintenance
immunosuppression of ATIP comprised of Cyclosporin,
1.5 ± 0.5 mg/kgBW/day or Azathioprine, 2 mg/kg BW/day
or Mycofenolate mofetil, 1 gm/day and Prednisolone, 7.5
± 2.5 mg/day. Control group patients were on standard
triple drug immunosuppression of Cyclosporin, 4.5 ± 1.5
mg/kgBW/day/Azathioprine, 2 mg/kg BW/day/Mycofeno-
late mofetil 2 gm/day and Prednisolone, 15 ± 5 mg/day.
Demographics of both groups were comparable.
Biopsies were performed whenever there was a sustained
rise of > 10% baseline serum creatinine (SCr) for 10 days.
Biopsies with chronic changes were included in this study
and diagnosed as per modified Banff criteria. [3,4] Mor-
phological evaluation was carried out using hematoxylin
and eosin, periodic acid Schiff, Jones' silver methaneam-
ine and Gomori's trichrome stains on 3 μm paraffin sec-
tions. C4d antibodies were tested using polyvalent anti-
human C4d antiserum (Biomedica Gruppe, Beckman
Coulter, Germany) by both techniques, immunofluores-
cence (IF) and immunohistochemistry (IHC) (using their
working protocol). Membranous nephropathy slides were
used as outside positive controls.
Chronic changes were classified into 2 patterns; those
with presence of stripped interstitial fibrosis, subintimal
diffuse/segmental arteriolar hyalinosis, negative C4d
deposits, absence of transplant glomerulopathies and
presence of periglomerular fibrosis were labeled as
chronic changes attributed to calcineurin inhibitor (CNI)
toxicity. The other group with variable fibrosis (and
absence of stripped fibrosis) with superadded lympho-
plasmacytic and/or neutrophilic infiltrates, with/without
chronic transplant glomerulopathy, C4d deposits (dif-
fuse/focal) across peritubular capillary membranes (by IF
or IHC) and chronic transplant vasculopathy were attrib-
uted to chronic B-cell (antibody) mediated rejections
with/without ongoing acute injuries. A subset of these
biopsies was also subjected to CD20 stain by IHC to con-
firm B-cell involvement.
Results
Out of the 1151 graft biopsies performed between January
2004 to December 2007, 135 (11.8%) biopsies with
chronic changes were reviewed. In total there were 107
out of 974 (10.98%) biopsies belonging to ATIP group,
and 31 out of 177 (17.5%) biopsies from the control
group showing chronic changes. Hypertension (with BP >
130/90 mmHg) was noted in 71 (66.4%) the ATIP
patients and 13 (41.9%) controls. Proteinuria (with 24
hours urinary protein leak of > 800 mg) was recorded in
46/107 (43%) ATIP and 25/31 (80.6%) controls.
In ATIP, 77/107 (71.9%) biopsies and in controls, 15/31
(48.4%) biopsies qualified for chronic changes attributed
to CNI toxicity (figure 1a, b). Chronic changes due to
immune mediated injuries were noted in 30/107 (28.1%)
ATIP group and 16/31 (51.6%) controls (figure 2).
CNI toxicity in ATIP group was noted in 63 males and 14
females with mean age of 34 years (range: 15–63 years)
with a mean follow-up of 4.09 years (range: 0.66–8.98
years).
Their mean SCr was 3 mg % (range: 0.8–12.9 mg %).
CNI toxicity in the control group was noted in 10 males
and 5 females with a mean age of 34 years (range: 17–52
years) with a mean follow-up of 5 years (range: 0.45–9.21Diagnostic Pathology 2009, 4:4 http://www.diagnosticpathology.org/content/4/1/4
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years). Their mean SCr was 3 mg % (range: 1.6–4.13 mg
%).
In the ATIP group, chronic ongoing immune injury was
noted in 24 males and 6 females with a mean age of 33.6
years (range: 12–56 years) with a mean follow-up of 4.53
years (range: 0.6–9.11 years) and their mean SCr was 3.02
mg% (range: 1.2–8.3 mg %).
In control group, chronic ongoing immune injury was
noted in 11 males and 5 females with mean age of 32.8
years (range: 11–67 years) with mean follow-up of 4.63
years (range: 0.65–8.24 years) and their mean SCr was 3.8
mg% (range: 1.6–8.5 mg %). The results are mentioned in
table 1.
Discussion
Renal transplantation is the best therapeutic option for
patients with end-stage renal disease. However acute rejec-
tions, infections, recurrence and drug toxicity are the
major limitations for graft/patient loss in the first year of
transplantation and chronic rejections are added to the
list to lead to graft and patient loss later on. [5-7]
CRAD has been defined as a progressive renal dysfunc-
tion, independent of acute rejection, drug toxicity and
recurrent/de novo nephropathy with histological changes
of vascular intimal hyperplasia, tubular atrophy, intersti-
tial fibrosis and chronic transplant glomerulopathy. Inju-
ries associated with CNI appear to be very common. The
pathophysiology of CRAD is complex and multi-factorial.
Both allo-antigen dependent factors like acute rejections,
HLA matching, ABO incompatibility, donor-specific anti-
bodies, inadequate immunosuppression, and allo-anti-
gen independent factors like donor age, living-related/
deceased donor, ischemia reperfusion injury, CNI/viral
related injuries, hypertension, hyperlipidemia, diabetes
mellitus, etc. are involved in its causation. The 8th consen-
sus meeting for Banff classification in 2005 decided to
eliminate the term chronic allograft nephropathy (CAN)
and replace it with chronic alloimmune versus non-
immune injury. [3,4]
We have been able to effectively address the problems of
acute T-cell mediated rejections and infections in the first
year of transplantation with continuous modifications of
ATIP whereby we have achieved prope tolerance. [8-10]
However we have not been able to address to B-cell anti-
body mediated rejections and CRAD. We have seen that
our patients present with a standard pattern of slow
decrease in glomerular filtration rate (GFR) reflected by
progressive increase in serum creatinine (SCr), hyperten-
a Atubular glomeruli surrounded by interstitial fibrosis in chronic allograft dysfunction associated with chronic Calcineurin  inhibitor toxicity, Hematoxylin and eosin stain, × 100 Figure 1
a Atubular glomeruli surrounded by interstitial fibrosis in chronic allograft dysfunction associated with chronic Calcineurin 
inhibitor toxicity, Hematoxylin and eosin stain, × 100. b Small caliber artery showing subintimal segmental hyalinosis (arrow 
head) as part of chronic CNI toxicity, Periodic Acid Schiff stain, × 200.Diagnostic Pathology 2009, 4:4 http://www.diagnosticpathology.org/content/4/1/4
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sion in about 66.4% of ATIP patients and 41.9% controls,
with/without proteinuria within the nephrotic range.
ABO antibodies were not the confounding factors in our
patients. We believe that those anti-HLA and non-HLA
antibodies that could not be abrogated by the ATIP group
were responsible for the chronic changes that would even-
tually lead to graft loss.
We hypothesize that in ATIP group, exhaustion of the T-
cell repertoire leads to free availability of endothelial sites
to the drug and hence it eventually causes chronic graft
attrition.
The two groups in this study are unequal in size since
most of our patients opt for transplantation with ATIP due
to its overwhelming benefits. The salient features noted in
this study are that beyond one year of transplantation,
long term effects of ATIP are:
1. markedly reduced requirement of immunosuppression
2. Even lower CNI dose leads to chronic changes eventu-
ally causing graft attrition as noted in 71.9% ATIP biopsies
vs. 48.4% controls.
3. Partial protection from immune injury as observed in
28.1% ATIP biopsies vs. 51.6% controls.
Further studies are ongoing to study donor specific anti-
bodies, non-specific antibodies and the role of MICA anti-
bodies on graft loss.
Conclusion
Retrospective evaluation of renal allograft biopsies shows
that transplantation using ATIP yields lesser incidence of
chronic immune injuries as compared to controls and
have a higher incidence of chronic CNI toxicity even at
lower doses.
CD20 stain showing B-cells (arrow) in ongoing chronic rejection, × 200 Figure 2
CD20 stain showing B-cells (arrow) in ongoing chronic rejection, × 200.Diagnostic Pathology 2009, 4:4 http://www.diagnosticpathology.org/content/4/1/4
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Table 1: Chronic changes noted in renal allograft biopsies of 2 groups, Ahmedabad Tolerance Induction Protocol (ATIP) vs. controls:
Biopsies ATIP Controls
(n = 1151) (n = 974) (n = 177)
Chronic changes (n = 135) 107 (10.98%) 31 (17.5%)
Mean follow-up (months) (range) 130.9 (23–277) 151.9 (13.9–280)
Male: female 87:20:00 21:10
Hypertension (BP > 130/90 mm Hg) 71 (66.4%) 13 (41.9%)
Proteinuria (24 hrs urine albumin > 800 mg) 46 (43%) 25(80.6%)
HISTOPATHOLOGY
Interstitial fibrosis+ tubular atrophy 107 (100%) 31 (100%)
Focal global sclerosis 50 (46.7%) 21 (67.7%)
Chronic transplant glomerulopathy 35 (32.7%) 15 (48.4%)
C4d deposits 2(1.9%) 6 (19.4%)
Acute on chronic calcineurin inhibitor toxicity 77 (71.9%) 15 (48.4%)
Acute on chronic T/B cell rejection 30 (28.1%) 16 (51.6%)